United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
| Key metrics |
|---|
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for BRAINSTORM CELL THERAPEUTICS INC.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Actual |
|---|
| Forecast |
|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|
| ROE | 116.14% | 67.31% | 40.06% | 28.62% | 22.29% | 18.38% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| Total Assets | $1,022.00K | $993.00K | $993.00K | $993.00K | $993.00K | $993.00K |
| Net Income | -$10,307.00K | -$10,130.22K | -$10,077.77K | -$10,083.03K | -$10,104.83K | -$10,198.63K |